RCI Hospitality Holdings (RICK) Corporate Presentation from NobleCon18Research, News and Market Data on RCI Hospitality HoldingsNobleCon 18 Complete Rebroadcast
|
RCI Hospitality Holdings (RICK) NobleCon18 Presentation Replay
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.
‌


Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News
‌


6/23/2026
Health
Eledon Pharmaceuticals (ELDN) – Eledon Presents Data Update From Phase 2 Trial With Clinical Trial Plans
Long-Term Outcomes Favor Tegoprubart. Eledon presented long-term data from its Phase 2 BESTOW trial at the American Transplantation Congress (ATC). The BESTOW trial tested tegoprubart as part of the immunosuppressive regimen...
2 min read
‌


6/22/2026
Economy
Alan Greenspan, the Most Powerful Central Banker of His Era, Dies at 100
Alan Greenspan, who chaired the Federal Reserve for more than 18 years across four presidential administrations and became the most recognizable central banker in modern history, died Monday at his...
3 min read
‌


6/22/2026
Health
Release – EverythingALS to Host NeuroSense in a Community Event Named: PrimeC – Connecting the Dots
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that EverythingALS will host a conversation built around a look...
5 min read
‌


6/22/2026
Health
Release – Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced new long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney transplantation, presented in oral and poster...
9 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.